Iontophoretic Co-delivery of NAD⁺ and KPV Rapidly Suppresses Systemic hs-CRP in Humans

¹Pain and Palliative Care Specialist, Mexico
²Ruben B Timmons, Pain Medicine in Pensacola, FLorida, USA
³CEO & Co-Founder, RegenerAge Clinic, Mexico
⁴Interventional Pain Management Specialist, Mexico

*Corresponding Author: Joel I. Osorio, CEO & Co-Founder, RegenerAge Clinic, Mexico, Phone: +1 7734417730, Email: [email protected], [email protected]

Received Date: May 26, 2026
Published Date: August 24, 2026

Citation: Korth C, et al. (2026). Iontophoretic Co-delivery of NAD⁺ and KPV Rapidly Suppresses Systemic hs-CRP in Humans. Mathews J Dermatol. 10(1):66.

Copyrights: Korth C, et al. © (2026).

ABSTRACT

High-sensitivity C-reactive protein (hs-CRP)—an ultrasensitive assay of the acute-phase protein C-reactive protein that tracks the magnitude of systemic inflammatory burden—was used to enroll 120 adults (hs-CRP ≥ 5 mg L⁻¹) into an open-label, parallel-group clinical study evaluating the safety and anti-inflammatory efficacy of a self-contained transdermal iontophoretic patch delivering nicotinamide adenine dinucleotide (NAD⁺, 500 mg) and the tripeptide Lys-Pro-Val (KPV, 10 mg) over 12 h. Forty participants received KPV monotherapy delivered via the ACTIVApatch® IontoGo™ 12.0 transdermal iontophoretic device; another forty received NAD⁺ monotherapy using an identical patch; and the remaining forty received the combination of NAD⁺ + KPV through the same patch platform, with hs-CRP measured at baseline and again on Day 7. The combination arm demonstrated a mean absolute Δhs-CRP of –9.82 ± 1.26 mg L⁻¹ (93 % reduction; AUC₁₋₇ = 26.9 ± 9.5 mg·d L⁻¹), significantly exceeding reductions observed with either monotherapy (one-way ANOVA F(2,117) = 32.6, p = 6×10⁻¹²; Tukey-adjusted p < 0.001). Mixed-effects modelling demonstrated a highly significant Group × Day interaction (χ² = 102.4, p < 10⁻¹⁵), confirming that the trajectory of hs-CRP reduction varied by treatment arm. Within 24 h the combination patch drove a substantially steeper decline than either NAD⁺ or KPV monotherapy, evidencing a faster pharmacodynamic onset. This accelerated, synergistic suppression of a systemic-inflammation biomarker represents a clear, quantifiable performance advantage that is directly material to the claimed invention’s novelty and utility. The hs-CRP assay lower limit of quantification was 0.50 mg L⁻¹ (intra-assay CV < 5 %). No serious adverse events were reported. These results unexpectedly demonstrate that simultaneous iontophoretic delivery of NAD⁺ and KPV yields synergistic, rapid, and durable suppression of systemic inflammation, supporting its potential to mitigate risk across a spectrum of inflammation-driven diseases, including cardiovascular disorders, autoimmune arthritis, inflammatory bowel disease, sepsis, metabolic syndrome, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, postoperative complications, and malignancy-associated inflammation.

Keywords: Iontophoresis; NAD⁺; KPV; C-Reactive Protein; Inflammation; Combination Therapy